Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 31, 2026

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

[Pathogen reduction for platelets: available techniques and recent developments].

G Andreu1

  • 1GIP-Institut national de la transfusion sanguine (INTS), Paris, France. gandreu@ints.fr

Transfusion Clinique Et Biologique : Journal De La Societe Francaise De Transfusion Sanguine
|July 5, 2011
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transfusion-associated hazards: A revisit of their presentation.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2018
Same author

Prevention of transfusion-transmitted cytomegalovirus (CMV) infection: Standards of care.

Vox sanguinis·2014
Same author

Education in transfusion medicine for medical students and doctors.

Vox sanguinis·2013
Same author

[Errors of red cell concentrates recipients: method of analysis using the adverse events notified to the hemovigilance network in 2009].

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2012
Same author

[Transfusion serious adverse events and root cause analysis].

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2012
Same author

[Pathogen inactivation technologies: a complex but necessary debate].

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2011
Same journal

Albumin priming enables safe and effective red blood cell exchange in low-weight children with sickle cell disease.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2026
Same journal

Catastrophic CD34+ autologous hematopoietic stem cell collection despite sustained mobilization and solutions to rescue the harvests.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2026
Same journal

Title of the study: Corrected Count Increment as a Predictor of Early Graft Dysfunction and Mortality Following Living Donor Liver Transplantation.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2026
Same journal

TLR4/MD-2 complex promotes transfusion-related acute lung injury pathogenesis through the activation of the AP-1 and NF-κB signaling pathways.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2026
Same journal

The Strategic Utility of Cryopreserved Platelets in Outer Space.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2026
Same journal

Genotyping of Human Neutrophil Antigen-3 by High Resolution Melting Analysis in Southern Thai Blood Donors.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2026
See all related articles

Pathogen reduction technologies enhance the safety of blood components like platelets. The Intercept® system, using psoralen and UVA light, has extensive documentation supporting its widespread clinical use.

Area of Science:

  • Blood banking and transfusion medicine
  • Microbiology and infectious disease control
  • Biotechnology and medical device development

Context:

  • The pursuit of microbiological safety in blood components, akin to plasma-derived drugs, spurred pathogen reduction research in the 1990s.
  • A 2007 consensus conference outlined implementation strategies for these critical safety processes.
  • Platelet concentrates have seen the development of multiple pathogen reduction technologies, with varying levels of clinical adoption.

Purpose:

  • To review the development and implementation status of pathogen reduction technologies for blood components, particularly platelet concentrates.
  • To compare the clinical and scientific documentation supporting different pathogen reduction processes.

Summary:

  • Three main pathogen reduction processes for platelet concentrates are under development or in clinical use: UV-C only (preclinical), Mirasol® (riboflavin/UV-A/UV-B, CE marked), and Intercept® (psoralen/UV-A, CE marked).

More Related Videos

Purification of Platelets from Mouse Blood
05:41

Purification of Platelets from Mouse Blood

Published on: May 7, 2019

Routine Screening Method for Microparticles in Platelet Transfusions
09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

Related Experiment Videos

Last Updated: May 31, 2026

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

Purification of Platelets from Mouse Blood
05:41

Purification of Platelets from Mouse Blood

Published on: May 7, 2019

Routine Screening Method for Microparticles in Platelet Transfusions
09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

  • The Intercept® process, established since 2002 and licensed in multiple European countries, possesses a substantial body of evidence from in vitro studies to post-marketing surveillance.
  • This documentation for Intercept® exceeds that of other novel blood safety innovations at their introduction.

    • Impact:

    • Highlights the advanced state of evidence for the Intercept® pathogen reduction system in platelet concentrates.
    • Provides a comparative overview of pathogen reduction technologies, aiding informed decisions in blood banking.
    • Underscores the importance of comprehensive documentation for the successful implementation of new transfusion safety measures.